| Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms |
|
Archives of Pathology & Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years |
|
Blood Advances |
Aplastic Anemia |
| Silver lining: reduced relapse with chronic GVHD after transplant for MDS |
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Graft Versus Host Disease (GVHD), Myelodysplastic Syndromes (MDS) |
| Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency |
|
Blood Transfusion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
